By Sarah Sorscher*, JD/MPH Candidate, Harvard Law School & Sara Crager, MD/PhD Candidate, Yale Editorial Policy Text of H.R. 1427 Summary Last week, Rep. Henry Waxman and several other representatives unveiled the latest version of a bill designed to lower the price of drugs by encouraging generic competition in biological products (“biologics”). Biologics are products derived from living processes and used to prevent, treat, or cure human illness. Most drugs, in contrast, are synthesized using chemical reactions. Biologics include products such as vaccines, blood-derived products, antibodies, ... Read More...
Archive for the ‘Patent’ Category
In re Bilski Redefined? By Briahna Gray – Edited by Anthony Kammer In re Lewis Ferguson, Darryl Costin and Scott C. Harris Federal Circuit, March 6, 2009, Serial No. 09/387,823 Order On March 6, 2009, the Federal Circuit Court of Appeals upheld a ruling by the Board of Patent Appeals and Interferences that a marketing paradigm for multiple independent software companies fashioned by Lewis Ferguson, Darryl Costin, and Scott C. Harris was not patentable under the U.S. Patent Act, 35 ... Read More...
Eli Lilly Granted Stay Extension, Prevents Teva’s Generic Alternative Until March 9th By Brian Kozlowski – Edited by Anna Lamut Eli Lilly & Co. v. Teva Pharma Federal Circuit, February 24, 2009, No. 2009-1071 Opinion On February 24th, the Federal Circuit affirmed two to one an order by the United States District Court for the Southern District of Indiana extending the 30-month statutory stay on FDA approval of Teva Pharmaceuticals‘ generic version of Eli Lilly‘s postmenopausal osteoporosis drug, Evista®. The ... Read More...
Federal Circuit, in a 2-1 Decision, Affirms Nonobviousness Determination in Medical Supply Case; Split Highlights Difficulty of Claim Construction By Chris Kulawik –- Edited by Stephanie Weiner Kinetic Concepts, Inc. v. Blue Sky Medical Group, Inc. Federal Circuit, February 2, 2009, Nos. 07-1340, 07-1341, & 07-1342 Slip Opinion In a 2-1 split, the Federal Circuit affirmed a nonobviousness determination in a contentious dispute between medical technology companies. The case turned on the construction of the claim term “treating a wound” ... Read More...
Federal Circuit Affirms Judgment Against Qualcomm, Limits Remedy of Patent Unenforceability By Aaron Dulles – Edited By Stephanie Weiner Qualcomm Inc. v. Broadcom Corp., Federal Circuit, December 1, 2008, No. 2007-1545 & 2008-1162 Slip opinion On December 1, 2008, the Federal Circuit affirmed in part the District Court for the Southern District of California, no. 05-CV-1958, holding that Qualcomm breached its duty to disclose relevant video-compression technology patents during its participation in a standards-setting organization (“SSO”). However the Federal Circuit ... Read More...
